Back to OfferingsGain Unparalleled Insights with the 2024 IDN Oncology Annual Trend Report
Integrated delivery networks (IDNs) are often the most complicated, dissimilar, and least understood customer segment in healthcare, with a significant and growing impact on prescription drug utilization. As a pharmaceutical manufacturer, understanding their influence is no longer optional, but essential.
HMP MAI helps subscribers understand IDNs’ pharmaceutical management strategies and decision-making processes—in aggregate and at the account level. Our primary and secondary research illuminates IDNs' financial control practices, clinical oversight, and opportunities for engagement. In addition, our proprietary IDN archetyping methodology empowers our subscribers to successfully navigate this important segment.
The 2024 IDN Oncology Annual Trend Report is now available! Covering 147 IDNs across all US regions, our report provides unique insights into the current trends and challenges in oncology through a comprehensive and rigorous methodology. Highlights include:
- Growing Oncology Reach: IDNs are seeing increased patient volumes and referrals, enhancing their dispensing power.
- Sophisticated Drug Management: Understand the impact of advanced tools like formularies and high-cost drug reviews on patient access.
- Effective Engagement: Our new playbook offers tailored strategies to connect with oncologists and pharmacists.
Armed with these insights, you can:
- Tailor your approach to IDN decision-makers
- Optimize your product positioning
- Align your offerings with IDN priorities and processes
Schedule a brief meeting with Ramon for more information on how the 2024 IDN Oncology Annual Trend Report can elevate your business.
Additional Resources
